To improve the website's functionality, we use cookies, including third-party cookies. Read our Privacy Policy for more information
I AgreeAnalysis of Psychotic Disorder Treatment market covering 30 + countries including analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more
At present, the global psychotic disorder treatment market accounts for US$ 13.6 billion and is projected to surge past a valuation of US$ 24.5 billion by the end of 2032.
Stress levels among the general population have increased notably over the past few years and this has led to an increase in the incidence of psychotic disorders such as bipolar disorder, schizophrenia, etc.
Fact.MR forecasts worldwide revenue from psychotic disorder treatment to increase at a high CAGR of 6.1% between 2022 and 2032.
Report Attributes |
Details |
---|---|
Market Size (2022E) |
US$ 13.6 Billion |
Forecasted Market Value (2032F) |
US$ 24.58 Billion |
Global Market Growth Rate (2022-2032) |
6.1% CAGR |
North America Market Share (2022) |
21.3% |
Europe Market Share (2022) |
25.4% |
Key Companies Profiled |
|
Don't Need a Global Report?
Save 40% on Country & Region specific reports
Instances of people suffering from severe psychotic disorders and mental illnesses have been witnessing an increase over the past few years and are projected to follow the same trend throughout the forecast period.
Awareness of psychotic disorders and other mental disorders is increasing with government initiatives and efforts taken by health organizations to capably deal with the increasing caseload of mental disorder patients.
Changes in lifestyle, the prevalence of stress-inducing global and economic conditions, high-stress environments, early onset of mental disorders in teenagers, and increasing prevalence of depression are other factors that could drive demand for psychotic disorder treatment equipment and drugs across the forecast period.
Difficulty in winning approvals from regulatory authorities for new drugs and treatments is expected to discourage psychotic disorder drug manufacturers and have an adverse effect on market growth.
The psychotic disorder treatment market is anticipated to expand at a CAGR of 6.1% through 2032.
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
“Increasing Investments in R&D of Novel Treatment Drugs & Therapies”
The incidence of severe psychotic disorders has risen over the past few years owing to increased levels of stress in the general population. This has fuelled demand for schizoaffective treatment, bipolar disorder treatment, paranoid schizophrenia treatment, etc.
To find new therapies and treatments for these psychotic disorders healthcare organizations are investing heavily in research and development activities.
“Side Effects of Psychotic Disorder Drugs Denting Market Demand”
Psychotic disorder drugs have been known to have adverse effects after long-term use and this is expected to have a restraining effect on the overall market growth. The lack of availability of certain specific drugs for the treatment of psychotic disorder symptoms is also expected to have a negative impact on the market over the coming years.
Lack of awareness of psychosis treatment procedures among the general population is also expected to constrain market potential through 2032.
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
“New Market Entrants Can focus on Development of Novel Treatment Procedures & Drugs”
New entrants can create novel therapies and treatment solutions for psychotic disorder symptoms and carve out a chunk of the market share for themselves by disrupting the global psychotic disorder treatment industry landscape.
Cognitive-behavioral therapy for psychosis has been a popular psychotic disorder treatment over the past years and new market players could enhance this therapy by improving its treatment by investing more in its research. They could also invest in research to develop a completely novel therapy for the treatment of mental illnesses.
“Demand for Psychotic Disorder Treatment Highest in Europe”
The Europe psychotic disorder treatment market accounts for a total valuation of US$ 3.45 billion in 2022 and holds a notable market share of 25.4% in the global industry landscape.
Increasing prevalence of severe psychotic disorders and rising awareness of mental health issues are prime factors driving market growth in this region.
Surging cases of severe mental illnesses and rising focus on mental health in North America are anticipated to primarily propel psychotic disorder treatment demand in this region. Currently, the market in the region accounts for a sales revenue of US$ 2.89 billion and a market share of 21.3%.
Initiatives to increase awareness of mental health disorders and the early onset of mental health issues such as depression and OCD (Obsessive -compulsive disorder) are expected to drive psychotic disorder treatment market growth in the Asia Pacific region.
Homeopathic medicines for psychosis and natural medicines for psychotic depression are anticipated to witness a steady increase in demand through 2032.
Fact.MR, a market research and competitive intelligence provider has listed a complete regional assessment of the psychotic disorder treatment market in this latest research study.
Psychotic disorder treatment providers are pushing for the approval of new drugs and treatment therapies from regulatory bodies to fast-track the launch of these novel treatments.
- Premium Report Details -
- Let's Connect -
- Quick Contact -
- Get Started -
Get insights that lead to new growth opportunities
Buy NowGet A Special pricing for start-ups and universities
Enquiry Before Buying- Humble, Yet Honored -
The global psychotic disorder treatment market is valued at US$ 13.6 billion.
The psychotic disorder treatment market is set to reach US$ 24.58 billion by 2032.
Revenue from psychotic disorder treatment is slated to rise at 6.1% CAGR.
The China psychotic disorder treatment market is valued at US$ 843 million.